Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
The International Journal of Pharmacy Practice|March 10, 2011
Electronic capture of dispensing data by the New Zealand Intensive Medicines Monitoring Programme: a consultation study of community and hospital pharmacistsMira Harrison-Woolrych, Simon Jamieson, Muzaffar Malik, et al.Drug Safety|December 14, 2011
Cardiovascular events in patients taking varenicline: a case series from intensive postmarketing surveillance in New ZealandMira Harrison-Woolrych, Simran Maggo, Ming Tan, et al.Drug Safety|April 28, 2005
Incidence of thrombotic cardiovascular events in patients taking celecoxib compared with those taking rofecoxib: interim results from the New Zealand Intensive Medicines Monitoring ProgrammeMira Harrison-Woolrych, Peter Herbison, Rachael McLean, et al.Contraception|September 29, 2007
Hair loss with use of the levonorgestrel intrauterine deviceHelen Paterson, Jennifer Clifton, Dawn Miller, et al.European Journal of Clinical Pharmacology|February 9, 2012
Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centresMira Harrison-Woolrych, Linda Härmark, Ming Tan, et al.The Journal of Clinical Psychiatry|May 3, 2008
Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 casesSusanna E Palmer, Rachael M McLean, Peter M Ellis, et al.The British Journal of Psychiatry : the Journal of Mental Science|June 10, 2011
Nocturnal enuresis in patients taking clozapine, risperidone, olanzapine and quetiapine: comparative cohort studyMira Harrison-Woolrych, Keren Skegg, Janelle Ashton, et al.Drug Safety|December 15, 2010
Uterine perforation with the levonorgestrel-releasing intrauterine device: analysis of reports from four national pharmacovigilance centresKees van Grootheest, Bernhardt Sachs, Mira Harrison-Woolrych, et al.Drug Safety|June 30, 2020
Evaluation of a Web-Based, 'Purchase Event' Intensive Monitoring Method for Pharmacovigilance of Natural Health Products: Lessons and Insights from Development Work in New ZealandJoanne Barnes, Jane L Sheridan, Christine Yang Dong, et al.European Journal of Clinical Pharmacology|June 8, 2006
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?David W J Clark, Johanna StrandellPageof 4